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Abstract
Proteasome inhibitors have provided a significant advance in the treatment of multiple myeloma (MM). Consequently, there
is increasing interest in developing strategies to target E3 ligases, de-ubiquitinases, and/or ubiquitin receptors within the
ubiquitin proteasome pathway, with an aim to achieve more specificity and reduced side-effects. Previous studies have
shown a role for the E3 ligase HUWE1 in modulating c-MYC, an oncogene frequently dysregulated in MM. Here we
investigated HUWE1 in MM. We identified elevated expression of HUWE1 in MM compared with normal cells. Small
molecule-mediated inhibition of HUWE1 resulted in growth arrest of MM cell lines without significantly effecting the
growth of normal bone marrow cells, suggesting a favorable therapeutic index. Studies using a HUWE1 knockdown model
showed similar growth inhibition. HUWE1 expression positively correlated with MYC expression in MM bone marrow cells
and correspondingly, genetic knockdown and biochemical inhibition of HUWE1 reduced MYC expression in MM cell lines.
Proteomic identification of HUWE1 substrates revealed a strong association of HUWE1 with metabolic processes in MM
cells. Intracellular glutamine levels are decreased in the absence of HUWE1 and may contribute to MYC degradation.
Finally, HUWE1 depletion in combination with lenalidomide resulted in synergistic anti-MM activity in both in vitro and
in vivo models. Taken together, our data demonstrate an important role of HUWE1 in MM cell growth and provides
preclinical rationale for therapeutic strategies targeting HUWE1 in MM.
Introduction
Multiple Myeloma (MM) is a hematological neoplasm
characterized by clonal proliferation of malignant plasma
cells in the bone marrow (BM). The use of proteasome
inhibitors (PIs) to disrupt the ubiquitin proteasome system
(UPS) has provided a significant therapeutic advance, and
highlights the importance of this pathway in MM [1].
Bortezomib, the first-in-class PI, is a widely used compo-
nent of both frontline and relapsed MM therapy, while
second generation PIs, carfilzomib and ixazomib, are
approved for relapsed and refractory MM [1, 2]. Despite
their success, acquired drug resistance and dose-limiting
side effects can limit their clinical utility [3–6] and there is
growing interest in targeting other components of the UPS.
The UPS plays a central role in protein homeostasis
through the targeted destruction of misfolded proteins and
regulatory proteins that control many critical cellular pro-
cesses. Proteins are recruited for degradation by the process
of ubiquitination, an enzymatic cascade involving three
* Lisa J. Crawford
lisa.crawford@qub.ac.uk
1 Patrick G Johnston Centre for Cancer Research, Queen’s
University Belfast, Belfast, UK
2 Department of Oncology and Metabolism, Sheffield Myeloma
Research Team, Medical School, University of Sheffield,
Sheffield, UK
3 Department of Medical Oncology, The LeBow Institute for
Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana
Farber Cancer Institute, Harvard Medical School, Boston, MA,
USA
4 Cell Biology Unit, University Medical Center Mainz,
Mainz, Germany
Supplementary information The online version of this article (https://
doi.org/10.1038/s41388-020-1345-x) contains supplementary
material, which is available to authorized users.
1
2
3
4
5
6
7
8
9
0
()
;,
:
1
2
3
4
5
6
7
8
9
0
()
;,:
types of enzymes. An E1 enzyme activates ubiquitin and
connects it to an E2 enzyme; an E3 ligase then mediates the
transfer of ubiquitin to the target protein, thereby providing
substrate specificity. The process can also be reversed by a
group of proteases known as de-ubiquitinating enzymes
(DUBs). Altered regulation of UPS enzymes has been
associated with transformation and tumorigenesis [7, 8].
E3 ligases and DUBs, in particular, present ideal therapeutic
candidates as they enable direct targeting of aberrant sig-
naling pathways. A prime example of this is
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immunomodulatory drug (IMiD)-induced degradation of
the transcription factors IKZF1 and IKZF3 through its
binding to cereblon, the substrate receptor for the Cullin-4
E3 ligase complex [9]. Preclinical studies have highlighted
a number of other DUBs and E3 ligases that present good
therapeutic targets in MM [10–13].
HUWE1 is a large (482 kDa) HECT-domain E3 ligase
that is involved in the regulation of key proteins such as c-
MYC (MYC), p53 and MCL-1 (ref. [14]). Dysregulation of
HUWE1 has frequently been associated with tumorigenesis
and mutations in HUWE1 have recently been identified in
MM patients [14, 15]. HUWE1 acts as both an oncogene
and tumor suppressor depending on cell context. There are
conflicting reports of the role of HUWE1 in regulating the
oncogene c-MYC (MYC). In one model, HUWE1 regulates
the stability of MYC through K48-linked ubiquitination and
knockdown of HUWE1 leads to increased MYC and drives
tumor progression [16]. Conversely, in other tumor types
HUWE1 activates transcription of MYC through K63-linked
ubiquitination and HUWE1 silencing or inhibition prevents
MYC signaling and reduces tumor cell proliferation [17, 18].
These contradictory observations suggest that HUWE1 may
play a cell-type and context-dependent role in MYC reg-
ulation. Pathological activation of MYC is a common feature
of B-cell malignancies, including MM [19, 20]. High
expression of HUWE1 has been demonstrated to specifically
correlate with MYC-driven lymphomas [21], however the
role of HUWE1 in regulating MYC in MM is unknown.
In this study, we show that HUWE1 is highly expressed
in MM compared with healthy plasma cells. Using small
molecule inhibitors and loss-of-function approaches, we
demonstrate an essential role of HUWE1 in promoting MM
growth in both in vitro and in vivo models. We further
demonstrate that HUWE1 depletion induces MYC degra-
dation in cell line models and patient-derived MM cells.
Results
HUWE1 is dysregulated in MM
Through the use of UPS topic-defined microarray analysis
of MM cell lines, we previously identified a number of
UPS-related genes, including HUWE1, with increased
expression in MM compared with normal CD138+ plasma
cells (Supplementary Fig. 1a, b) [22]. Further analysis of
three independent gene expression datasets revealed a pro-
gressive increase in expression of HUWE1 through a
spectrum of plasma cell diseases (Fig. 1a–c). Similarly,
immunohistochemical analysis of HUWE1 expression in
BM from healthy donors (n= 3), patients with MGUS
(n= 3), and MM (n= 25) demonstrated a significant
increase in expression of HUWE1 in MM plasma cells,
compared with normal controls (p= 0.014; Fig. 1d, e).
Furthermore, analysis of HUWE1 gene expression and
overall survival of MM patients using data from the
CoMMpass study, revealed that patients expressing higher
levels of HUWE1 exhibit a significantly reduced overall
survival compared with those with lower expression (log-
rank p= 0.025; Fig. 1f).
In addition to dysregulated expression of HUWE1
demonstrated here, mutations in HUWE1 have recently
been identified in a small proportion of MM patients (5.7%)
[15]. These are predominantly missense mutations dis-
tributed across the coding sequence and are significantly
associated with the t(11;14) subgroup. A proportion (7%) of
mutations reported in MM patients are found in the
dimerization region of HUWE1, which based on previous
studies are likely to lead to increased activity [23, 24],
however, the effect of the majority of mutations has yet to
be determined. Through analysis of publically available
MM cell line data (www.keatslab.org) we identified cell
lines with HUWE1 mutations and subsequently confirmed
HUWE1 mutations in five MM cell lines (U266, XG-1,
XG-2, KMS-27, and H1112) by Sanger sequencing (Sup-
plementary Fig. 1c). In line with MM patient data, HUWE1
mutations were predominantly found in cell lines with a t
(11;14) translocation and are distributed in a similar manner
(Supplementary Fig. 1c-d). HUWE1 protein expression in
mutant cell lines was compared with expression in five MM
cell lines with wild type (WT) HUWE1 (JJN3, MM.1S,
ANBL-6, KMS-18, OPM-2). HUWE1 protein expression
was significantly lower in the H1112 cell line (p= 0.002),
which carries a splice-site mutation, compared with
HUWE1 wild-type cell lines. However, UbiQapture-Q
assays demonstrated HUWE1 catalytic activity, as
Fig. 1 HUWE1 is dysregulated in multiple myeloma. HUWE1
expression in CD138+ cells from (a) normal donors (n= 16),
monoclonal gammopathy of undetermined significance (MGUS; n=
22), smoldering MM (SMM; n= 24), and newly diagnosed MM
patients (n= 72); published dataset GSE6477, (b) normal donors (n=
22), MGUS (n= 44), and SMM (n= 14); published dataset GSE5900,
and (c) MGUS (n= 7), MM (n= 39) and plasma cell leukemia (PCL;
n= 6) patients; published dataset GSE2113. d Representative immu-
nohistochemistry (IHC) images of dual staining for CD138 and
HUWE1 in healthy donor bone marrow, patients with MGUS and MM
patients. HUWE1 red staining, CD138 dark brown/black staining, blue
counterstain (original magnification ×10 and ×20). e Nuclear HUWE1
DAB staining intensity from healthy donors (n= 3), MGUS (n= 3),
and MM (n= 25). f Kaplan–Meier curves for 5 year overall survival
relative to HUWE1 expression (CoMMpass dataset IA14 release); ≥33
percentile n= 244 (178 censored), ≤33 percentile n= 488 (378 cen-
sored); censored cases are represented by vertical ticks. g Top panel—
HUWE1 expression in MM cell lines; Bottom panel—HUWE1
activity in MM cell lines (HUWE1 auto-ubiquitination is used as a
read-out for catalytic activity). h Densitometry analysis of HUWE1
expression and activity in MM cell lines; n= 3. a, b, c, e One way
ANOVA was used for statistical analysis; *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001.
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measured by auto-ubiquitination activity, in all cell lines
including H1112 (Fig. 1g, h).
HUWE1 inhibition or depletion decreases cell
viability and induces cell cycle arrest in MM cells
To determine whether HUWE1 has any functional sig-
nificance in MM, we first analyzed the effect of small
molecule inhibition or shRNA knockdown of HUWE1 on
the growth and survival of MM cell lines. HUWE1 inhi-
bitors BI8622 and BI8626 have been previously identified
and characterized [16, 25]. Inhibition of HUWE1 auto-
ubiquitination confirmed on-target activity of the inhibitors
(Supplementary Fig. 2a). Both inhibitors reduce the viabi-
lity of a panel of MM cell lines, including those resistant to
dexamethasone (MM.1R) and bortezomib (ANBL6-BR) in
a concentration-dependent manner (Fig. 2a). Furthermore,
no significant shift in sensitivity is observed when cell lines
are co-cultured with MM patient-derived BMSCs (Fig. 2b;
Supplementary Fig. 2b). A single treatment with IC50 dose
of BI8622/BI8626 significantly reduced the proliferation of
MM cells lines over 96 h (Fig. 2c; Supplementary Fig. 2c),
and analysis of cell cycle distribution demonstrated an
accumulation of cells in S (p ≤ 0.044) and G2/M (p ≤ 0.048)
with an associated decrease in G1 (p ≤ 0.0024; Fig. 2d).
Importantly, inhibition of HUWE1 has no significant effect
on the viability (Supplementary Fig. 2c) or colony forming
ability (Fig. 2e, f) of normal BM mononuclear cells, sug-
gesting a favorable therapeutic index.
For shRNA studies, JJN3 cells were transduced with
doxycycline-inducible lentivirus encoding three distinct
HUWE1–targeting shRNA constructs; cells transduced with
a non-targeting control (NTC) shRNA were used as a con-
trol. Following puromycin selection, cells were seeded at a
density of 3 × 105 cells/ml and proliferation evaluated over
96 h. Upon addition of doxycycline, all shRNA sequences
reduced expression of HUWE1 (Fig. 2g), leading to
decreased proliferation (Fig. 2h). Effects on proliferation
were greatest using construct shHUWE1-3 (p= 0.008) and
this shRNA was used in subsequent experiments. As with
HUWE1 inhibitors, reduction in proliferation was main-
tained when HUWE1 knockdown cells were co-cultured
with BMSCs (Fig. 2i). Analysis of cell cycle distribution
72 h post-doxycycline induction demonstrated a significant
accumulation of cells in S-phase (p= 0.003) with an asso-
ciated decrease in G1 (p= 0.019), and this effect was
maintained 1 week post-treatment. This is consistent with
finding by Choe et al. who reported an S-phase arrest in
HUWE1-depleted cells [26]. While both inhibition and
knockdown of HUWE1 effectively block the proliferation of
MM cell lines, there is little associated activation of caspase-
induced apoptosis (Supplementary Fig. 2d-e) suggesting that
the effect of HUWE1 depletion is primarily cytostatic.
HUWE1 expression correlates with MYC expression
in MM
Qi et al. previously reported that HUWE1 parallels MYC
expression in MYC-driven B-cell lymphomas [21]. Here we
show that nuclear staining of HUWE1 in MM BM trephines
positively correlates with nuclear staining of MYC
(r= 0.49; p= 0.03; Fig. 3a, b). Furthermore, we demon-
strate that MYC expression comparably decreases along
with HUWE1 expression in knockdown cells (Fig. 3c).
Correspondingly, inhibition of HUWE1 with BI8622 and
BI8626 leads to decreased MYC expression across a panel
of HUWE1 wild-type and mutant cell lines and patient-
derived MM cells, with the exception of XG-1 HUWE1
mutant cell line. MYC mRNA levels are not altered in the
absence of HUWE1 (Supplementary Fig. 3a-b), indicating
that MYC is post-translationally regulated by HUWE1.
Ubiquitination assays demonstrate a decrease in K63- and
increase in K48-linked polyubiquitination of MYC when
HUWE1 is inhibited (Fig. 3e; Supplementary Fig. 3c)
suggesting that in the absence of HUWE1, MYC is targeted
for proteasomal degradation. This is further confirmed by
demonstrating that MYC protein expression is rescued in
HUWE1 inhibitor treated cells by addition of the protea-
some inhibitor bortezomib (Fig. 3f).
Identification of HUWE1 substrates in MM
To further elucidate the function of HUWE1 in MM, we
employed Snapshot proteomics to identify substrates of
HUWE1. This technique detects ubiquitination reactions in
Fig. 2 Inhibition or knockdown of HUWE1 halts MM cell pro-
liferation. a 24 h dose response of MM cell lines to BI8622 (left
panel) and BI8626 (right panel). b Dose response of JJN3 cells to
BI8622 when cultured alone or in co-culture with bone marrow stro-
mal cells (BMSCs) for 24 h. c Growth curve of JJN3 cells cultured in
the presence of 14 μM BI8622 or BI8626; DMSO treated cells were
used as a vehicle control. d Cell cycle distribution of JJN3 cells cul-
tured in the presence of 15 μM BI8622 or BI8626 for 24 h. e Repre-
sentative colony growth of mononuclear cells from healthy donors
cultured for 14 days in semi-solid methylcellulose based media in the
presence of 15 µM BI8622 or BI8626; DMSO treated cells were used
as a vehicle control. f Quantification of colonies after 14 days. g JJN3
cells expressing doxycycline‐inducible shRNAs targeting HUWE1 or
a non-targeting control (NTC) shRNA were treated with 1 μg/ml
doxycycline (dox). Expression of HUWE1 was analyzed by Western
blotting 72 h post-dox treatment. h Growth curve of JJN3 cells
expressing doxycycline‐inducible shRNAs or NTC shRNA; 72 h post-
dox treatment cells were seeded at 3 × 105/ml and growth was mon-
itored over 96 h. i Growth curve of JJN3 cells expressing NTC shRNA
or shHUWE1-3 cultured alone or in co-culture with HS-5 stromal
cells. j & k Cell cycle distribution of JJN3 cells expressing NTC
shRNA or shHUWE1-3 72 h (j) or 1 week (k) post-dox treatment. n ≥
3 for all experiments; paired t-test was used for statistical analysis;
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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whole cell lysates using protein microarrays as a substrate
platform. Microarrays were incubated with cell lysates from
NTC or HUWE1 knockdown cells, and pan-ubiquitin
chains detected. Data were obtained from 21,065 proteins,
and 2223 proteins demonstrated significant changes
(p < 0.05) in ubiquitination (Fig. 4a; Supplementary Table
1). Positive changes in M-value represent putative
HUWE1 substrates, while negative M-values represent
proteins with increased ubiquitination. In total, 1516 pro-
teins exhibited a statistically significantly decrease in
A
H & E CD138
HUWE1 MYC
r  =0.49
p = 0.03
B C
D
E F
Fig. 3 HUWE1 expression
correlates with MYC
expression in multiple
myeloma. a Representative IHC
from MM patient trephines:
hematoxylin and eosin (top left),
CD138 (top right), HUWE1
(bottom left), and MYC (bottom
right). b Correlation of nuclear
HUWE1 and nuclear MYC
DAB staining in MM patient
trephines (n= 20); staining
intensity was quantified using
QuPath. Correlation coefficient
and statistical analysis was
determined using Pearson’s test.
c HUWE1 and MYC protein
expression in JJN3 cells
expressing shHUWE1-3 24, 48
and 72 h post-treatment with
1 μg/ml doxycycline (dox).
d MYC protein expression in a
panel of HUWE1 wild-type
(WT) cell lines, HUWE1 mutant
cell lines and MM patient
samples cultured in the presence
of 15 μM BI8622 or BI8626 for
24 h; DMSO treated cells were
used as a vehicle control (VC).
e MYC ubiquitination following
HUWE1 inhibition. Left side of
blot shows MYC expression in
MM.1S cells cultured in the
presence of 15 μM BI8622 or
BI8626 (Input); right side of blot
shows ubiquitinated MYC
enriched from input lysate using
UBIQAPTURE-Q ubiquitin
affinity matrix. f MYC
expression in MM.1S cells
cultured for 6 h with 15 μM
BI8622 or BI8626 ±3 h pulse
with 20 nM bortezomib.
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ubiquitination in the absence of HUWE1. While some of the
smaller changes are likely to represent noise in the analysis,
no cut off in M-value was employed as these can also
indicate slight but highly reproducible modifications in
ubiquitination such as chain shortening or lengthening. Gene
ontology and ingenuity pathway analysis of putative sub-
strates of HUWE1 revealed a strong enrichment for meta-
bolic processes (Fig. 4b, c; Supplementary Fig. 4a-c). MM
cells display alterations in many metabolic pathways [27],
and proteins from pathways including glycolysis, glutami-
nolysis, and fatty acid metabolism exhibit modified ubiqui-
tination in the absence of HUWE1 (Supplementary Table 2).
As depletion of glutamine has been demonstrated to induce
a MM-specific degradation of MYC [28], similar to our
findings with HUWE1 inhibition or knockdown, we investi-
gated the effect of loss of glutamine on sensitivity of MM cell
lines to HUWE1 inhibitors. Comparable with previous find-
ings, we show decreased MYC expression in cells cultured
without L-glutamine (Supplementary Fig. 5a) and demon-
strate reduced sensitivity to HUWE1 inhibition in these cells
(Supplementary Fig. 5b). No changes to the ubiquitination
status of principle glutamine transporters (SLC1A5,
SLC38A1, and SLC38A2) were detected in HUWE1-
depleted cells, however, altered ubiquitination was identified
in a number of transporters, enzymes, and electrochemical
gradients related to glutamine metabolism (Supplementary
Table 2). We demonstrate that inhibition or knockdown of
HUWE1 results in a significant decrease in intracellular glu-
tamine levels in MM cell lines (p ≤ 0.012; Fig. 4d, e), sug-
gesting that reduction in glutamine contributes to MYC
degradation in the absence of HUWE1; future studies will
aim to dissect the mechanism behind this phenomenon.
Combination of HUWE1 depletion and conventional
MM therapies induces synergistic anti-MM activity
Proteasome inhibitors and IMiDs are critical components of
MM therapy. The combination of HUWE1 inhibitors with
carfilzomib enhanced the antiproliferative effects of either
agent alone, and combination index (CI) analysis demon-
strated some synergistic anti-MM activity (Fig. 5a; Supple-
mentary Fig. 6a). HUWE1 inhibitors in combination with the
IMiD lenalidomide similarly enhanced the antiproliferative
effects of either agent alone and exhibited strong synergistic
activity with both BI8622 and BI8626 at all doses tested (Fig.
5b; Supplementary Fig. 6b). Correspondingly, HUWE1
knockdown JJN3 cells are significantly more sensitive to
lenalidomide than their control counterparts, while there is no
change in sensitivity to carfilzomib (Fig. 5c, d). The
mechanism of strong synergy between HUWE1 depletion
and lenalidomide may be, in part, mediated through their
combined effects on MYC (Fig. 5e, f).
Fig. 4 Identification of HUWE1 substrates in multiple myeloma. a
Protein arrays were incubated with cell lysates from JJN3 cells
expressing NTC or shHUWE1, and pan-ubiquitin chains detected
using tandem ubiquitin binding entities (TUBE). Graph represents
significant changes in protein ubiquitination in the absence of HUWE1
(n= 2314), positive values indicate putative substrates; M-value
measures magnitude of change. b Top gene ontology processes enri-
ched in putative HUWE1 substrates (biological processes). c Top
networks enriched in putative HUWE1 substrates identified through
Ingenuity Pathway Analysis. d Intracellular glutamine concentration of
JJN3 cells cultured with vehicle control or 15 μM BI8622 or BI8626;
expressed as a percentage of vehicle control (n= 3). e Intracellular
glutamine concentration of JJN3 cells expressing NTC shRNA or
shHUWE1-3 ±1 μg/ml doxycycline (DOX); expressed as a percentage
of control (n= 3). Statistical significance was determined using paired
t-tests; *p ≤ 0.05, ***p ≤ 0.001.
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HUWE1 knockdown decreases MM tumor burden
in vivo
The pharmacokinetic properties for currently available
HUWE1 inhibitors BI8622 and BI8626 are unfavorable for
in vivo studies [16] and therefore we validated the in vivo
effect of HUWE1 depletion using inducible shRNA
knockdown JJN3 cells. We have previously demonstrated
that JJN3 cells produce an aggressive, short-term model of
myeloma in NSG mice, with mice exhibiting signs of
morbidity 3 weeks after tumor cell injection [29]. JJN3
NTC or JJN3 shHUWE1-3 cells were injected into NSG
mice and following the addition of doxycycline to the
drinking water 7 days post-tumor cell injection, mice were
Fig. 5 Synergistic activity of
HUWE1 inhibition or
knockdown with conventional
multiple myeloma therapies. a
MM.1S cells were treated with
BI8622 (7.5 or 15 μM) or
BI8626 (7.5 or 15 μM) plus
carfilzomib (2.5 and 5 nM) for
24 h and analyzed for viability.
bMM.1S cells were treated with
BI8622 (7.5 or 15 μM) or
BI8626 (7.5 or 15 μM) plus
lenalidomide (1 or 10 μM) for
72 h and analyzed for viability.
a and b display combination
index (CI) values whereby a CI
< 1 indicates synergy, 1
indicates an additive effect, and
>1 indicates antagonism (n= 3).
c Dose response of JJN3 cells
expressing doxycycline‐
inducible shHUWE1-3 or NTC
shRNA to carfilzomib; 72 h
post-dox treatment cells were
seeded at 3 × 105/ml, treated
with carfilzomib, and analyzed
for viability after 24 h (n= 3).
d Dose response of JJN3 cells
expressing doxycycline‐
inducible shHUWE1-3 or NTC
shRNA to lenalidomide; 72 h
post-dox treatment cells were
seeded at 3 × 105/ml, treated
with lenalidomide, and analyzed
for viability after a further 72 h
(n= 3). Statistical significance
was determined using paired t-
tests; *p ≤ 0.05, ***p ≤ 0.001.
e MYC protein expression in
MM.1S cells treated with
BI8622 or BI8626 alone
(15 μM), lenalidomide alone
(10 μM), or a combination of
both. f MYC protein expression
in JJN3 cells expressing
doxycycline‐inducible
shHUWE1-3 treated with
doxycycline alone (1 μg/ml),
lenalidomide alone (10 μM), or a
combination of both.
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treated with either lenalidomide or vehicle and monitored
for a further 2 weeks. Addition of doxycycline significantly
abrogated tumor growth by 13 days post-treatment as
measured by bioluminescence imaging (p= 0.03) and per-
centage of tumor cells (p= 0.0006; Fig. 6a, b, d, e); similar
effects were seen with single agent lenalidomide (p ≤ 0.006;
Fig. 6a, c–e). Furthermore, the combination of HUWE1
knockdown and lenalidomide significantly reduced tumor
burden compared with either treatment alone (p= 0.03; Fig.
6e). Immunohistochemical analysis of CD138/HUWE1 and
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Fig. 6 Effect of HUWE1
knockdown on multiple
myeloma tumor burden
in vivo. a Representative images
of tumor burden as assessed by
bioluminescent imaging (BLI):
shown are end stage images
(13 days post-treatment; 21 days
post-injection) for mice injected
with JJN3 cells expressing NTC
shRNA or shHUWE1-3, treated
with doxycycline (1 mg/ml) and
vehicle control or doxycycline
and lenalidomide (100 mg/kg).
b Tumor burden was quantified
(total flux as measured by BLI)
in mice injected with JJN3 cells
expressing NTC shRNA or
shHUWE1-3 at intervals for
13 days post-treatment with
doxycycline. c Tumor burden
was quantified (total flux as
measured by BLI) in mice
injected with JJN3 cells
expressing NTC shRNA at
intervals for 13 days post-
treatment with doxycycline plus
vehicle or lenalidomide. d End
stage tumor burden expressed as
fold change in total flux as
measured by BLI. e End stage
tumor burden expressed as a
percentage of human leukocyte
antigen (HLA) positive cells
from femora bone marrow
flushes. f Representative IHC
images of sections of distal
femur for each treatment group
dual stained with CD138/
HUWE1 or CD138/MYC
(original magnification ×10).
n= 8 mice/group; data are
presented as mean ± SEM;
statistical significance was
determined using one-way
ANOVA; *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001, ****p ≤ 0.0001.
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CD138/MYC validated HUWE1 knockdown in vivo and
demonstrated reduction in MYC expression and tumor
burden 13 days post-treatment with doxycycline, lenalido-
mide or a combination of both (Fig. 6f).
Discussion
HUWE1 is a large HECT-domain E3 ligase that catalyzes
ubiquitination of a wide range of protein substrates, impli-
cating it in the regulation of numerous cellular processes
including cell proliferation, apoptosis, replication, and DNA
damage response [26, 30–32]. It is therefore not surprising
that dysregulation of HUWE1 is associated with tumor-
igenesis. Whether HUWE1 possesses tumor promoting or
tumor suppressor activity is a matter of debate and appears
to be dependent on cell type. Overexpression of HUWE1
has been identified in many cancers, with one study
reporting increased expression of HUWE1 in 7 out of 9
tumor types [33]. Correspondingly, we found increased
HUWE1 in malignant compared with healthy plasma cells.
HUWE1 can be additionally dysregulated in MM through
mutation [15]. We identified MM cell lines expressing
HUWE1 mutations distributed in a comparable manner to
mutations identified in patients. HUWE1 expression and
activity was similar across both HUWE1 mutant and wild-
type cell lines. Based on data compiled by the Exome
Aggregation Consortium (ExAC) HUWE1 is predicted to
be intolerant to loss-of-function mutations (pLI score= 1).
Mutations in HUWE1 occur at moderate frequencies in
cancers [15] but are commonly associated with X-linked
intellectual disability where they can lead to altered or
enhanced activity [24, 34]. The association of HUWE1
mutations with t(11;14) in patients and cell lines suggests
that they may be of functional significance in this subgroup
and warrants further investigation. Together with our
observations and ExAC predictions it is likely that muta-
tions predominantly lead to altered function in MM rather
than total loss of activity. HUWE1 has generated interest as
a potential therapeutic target in a number of malignancies
[16, 20, 31, 35–37]. In this study we show that small
molecule inhibition or knockdown of HUWE1 effectively
reduces the proliferation of MM cells without affecting the
viability of healthy BM mononuclear cells. Importantly,
reduced proliferation was observed even when cells were
grown in the presence of BMSCs, which promote the
growth and survival of MM cells. Furthermore, knockdown
of HUWE1 significantly reduces tumor burden in an
aggressive in vivo model of MM validating its potential as a
therapeutic target in MM. Combination therapy consisting
of PIs or IMiDs form the backbone of MM treatment
regimes [38]. Here we demonstrate synergistic activity of
HUWE1 knockdown or inhibition with both classes of these
drug types. Combinations of HUWE1 inhibition and the
IMiD lenalidomide, in particular, lead to significantly
reduced tumor growth both in vitro and in vivo. Given the
potential of targeting HUWE1 in MM and other malig-
nancies, efforts are currently underway to generate HUWE1
inhibitors with improved physiochemical properties.
MYC, one of the most widely studied substrates of
HUWE1, is frequently dysregulated in MM. Regulation of
MYC by HUWE1 is context-dependent, with evidence to
support both K48- and K63-linked polyubiquitination
leading to degradation or activation of MYC, respectively
[17, 39]. Previous studies investigating the relationship
between HUWE1 and MYC have demonstrated that
HUWE1 is required for normal B-cell homeostasis [40, 41],
and regulates B-cell maturation through its effects on MYC
[41]. Furthermore, high HUWE1 expression has been spe-
cifically linked to MYC driven B-cell lymphoma [20]. In
this study, we explored the relationship between HUWE1
and MYC in MM, a terminally differentiated B-cell
malignancy. We found a positive correlation between
MYC and HUWE1 protein expression in MM, and
demonstrate that HUWE1 depletion leads to decreased K63-
ubiquitination and promotes proteasomal degradation of
MYC. This is in keeping with a previous studies reporting
K63-ubiquitination of MYC by HUWE1 [18] and demon-
strating reduced expression of MYC in murine B cells
deficient in HUWE1 [41]. Conversely, HUWE1 inhibition
does not affect steady state levels of MYC in a model of
colorectal cancer suggesting tissue specific regulation of
MYC by HUWE1 [16]. Taken together with earlier studies,
our findings indicate that regulation of MYC by HUWE1 is
specifically important in the regulation and survival of both
normal B cells and malignant B cells.
An ubiquitin-specific proteomics approach was adopted
to unravel the mechanisms underlying HUWE1 function in
MM. This analysis identified a large number of putative
HUWE1 substrates. Consistent with this, structural studies
have identified a conformational flexibility in HUWE1 that
is predicted to allow ubiquitination of a wide spectrum of
substrates [23, 42]. Moreover, HUWE1, in common with
other HECT family E3 ligases, can co-operate with different
E3s to catalyze ubiquitination, further expanding the num-
ber of target substrates [43–45]. Surprisingly, both gene
ontology and network analysis of these proteins revealed a
strong enrichment for metabolic processes. To date just one
study has reported a role for HUWE1 in regulating cancer
cell metabolism through K63-linked ubiquitination of the
glycolytic enzyme hexokinase 2 [35]. We identified a
number of other metabolic enzymes and transporters as
potential substrates of HUWE1, suggesting that, in MM,
HUWE1 may exhibit a broader effect on tumor metabolism.
Altered metabolism contributes to pathogenesis, acquired
drug resistance and immune evasion in MM [46–48]. MM
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cells are more dependent on both glycolysis and glutami-
nolysis than normal plasma cell counterparts [27]. Inter-
estingly, inhibition of glutaminolysis has been demonstrated
to induce MM cell-specific degradation of MYC [28],
mirroring the effects of HUWE1 inhibition. The reduction
of intracellular glutamine levels in the absence of HUWE1,
suggest that glutamine levels may play a role in MYC
regulation when HUWE1 is depleted. However, additional
studies are required to delineate the role of HUWE1 in
regulating MM cell metabolism, particularly in relation to
MYC-driven metabolic pathways.
In summary, accumulating evidence points to a context-
dependent role for HUWE1 in tumor pathogenesis. Our
study demonstrates that in MM, as with other B-cell types,
HUWE1 plays a vital role in cell proliferation and regula-
tion of MYC expression. Furthermore, downregulation of
HUWE1 enhances the antitumor activity of standard of care
therapies, particularly lenalidomide, highlighting the pro-
mise of therapeutically targeting HUWE1 in MM.
Materials and methods
Cell lines
HS-5, 293T, MM.1S, and ANBL-6 cells were purchased
from ATCC and OPM-2, and U266 and JJN3 cells were
purchased from DSMZ. XG-1 and XG-2 cells were a kind
gift from Dr Catherine Pellat-Deceunynck, INSERM,
France. H1112 and KMS-27 cells were a kind gift from Prof
Leif Bergsagel, Mayo Clinic, Arizona. All cell lines were
maintained according to providers instructions. ANBL6.WT
(wild-type), ANBL6.BR (bortezomib resistant), XG-1, and
XG-2 were supplemented with IL-6 (2 ng/ml). ANBL6.BR
cells were cultured in the presence of 5 nM bortezomib.
Cells were routinely tested for mycoplasma, and authenti-
cation using short tandem repeat profiling (STR) was con-
ducted by Eurofins Cell Line Authentication Service
(Ebersberg, Germany).
Primary samples
Bone marrow aspirates and trephines from MM patients
were obtained with ethical approval from the Northern
Ireland Biobank (approval # NIB12-0061) and those
involved gave their informed consent in accordance with
the Declaration of Helsinki. Human BM mononuclear cells
and slides were purchased from Stem Cell Technologies
(Cambridge, UK) for use as a normal control. CD138
expression is a hallmark of plasma cells and MM cells.
CD138+ cells were enriched from primary samples using
the AutoMACS system (Miltenyi Biotech, Germany)
according to the manufacturer’s instructions.
Bone marrow stromal cell (BMSC) culture and MM
co-culture assay
MM BMSCs were isolated from BM aspirates as previously
described [22]. MM cell lines or MM patient-BMSCs/HS-
5 stromal cell line were cultured either alone or together at
1:5 (BMSC/MM) ratio for 48 h, and cell proliferation was
measured using the CyQUANT cell proliferation assay, as
per manufacturers’ instructions (Thermo Fisher).
Colony forming unit (CFU) assays
Mononuclear cells from normal donors were cultured in
Methocult H4034 Optimum media (StemCell Technologies)
in the presence of 15 μM BI8622 or BI8626. After 2 weeks,
colonies were counted using a light microscope.
Immunohistochemistry
Bone marrow trephines were obtained from 25 MM patients,
3 monoclonal gammopathy of undetermined significance
(MGUS) patients, and 3 healthy subjects. Consecutive serial
sections cut from each FFPET block were cut onto poly-
lysine slides, dewaxed in xylene, and rehydrated through
graded alcohol. Heat-induced epitope retrieval was per-
formed in 10 mM citrate buffer pH 6.0 using a microwave
oven and endogenous peroxidase activity was inactivated
with 0.3% H2O2 in methanol. The following antibodies
were used for IHC – CD138 (MCA2459T, Bio-Rad, Hert-
fordshire, UK), HUWE1 (HPA002548, Merck, Feltham,
UK), MYC (ab32072, Abcam, Cambridge, UK), and uni-
versal Anti-Mouse/Anti-Rabbit (Vector Laboratories, Peter-
borough, UK). Immunoreactivity was visualized with
ImmPACT DAB peroxidase substrate (Vector Laboratories)
and nuclei were counterstained with haematoxylin. Images
were taken using blinded analysis with an Olympus BH-2
microscope fitted with an Infinity 3 camera (Lumerera) and
analyzed for DAB positivity using QuPATH [49].
Lentiviral transfection
Transient production of viral vectors encoding SMART-
vector Inducible Human HUWE1 shRNA (Dharmacon,
Chicago IL, USA) was carried out using 293T cells. 24 h
after transfection the media was refreshed and the culture
supernatant was harvested 24 h following medium
exchange, filtrated (0.45 μm), supplemented with polybrene,
and used to transduce MM cell lines or stored at −80 °C for
later use. FACS analysis was performed following trans-
duction to select for cells expressing the TurboRFP reporter
gene after treatment with 1 µg/ml doxycycline (Merck).
shRNA sequences are shown below. Cells infected with
vector expressing NTC shRNA were used as controls.
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H1 - ATCGAAAGAACGCAATGCT
H2 - TTCGGCACAAATCTACTTC
H3 – TGGACGAATGCCTAGCTGG
Cell assays
Cell viability and apoptosis was assessed using CellTiter-
Glo® and Caspase-Glo assays, respectively (Promega,
Southampton, UK). Proliferation was assessed using
CyQUANT (Thermo Fisher) according to the manu-
facturer’s instructions. Intracellular glutamine concentration
was measured using the Glutamine Assay Kit (Abcam)
according to the manufacturer’s instructions.
Cell cycle analysis
Cells were harvested, washed in phosphate-buffered saline
and cell cycle analyzed using either propidium iodide
staining or EDU incorporation. For propidium iodide
staining cells were fixed in 70% ethanol and subsequently
stained with 50 μg/ml propidium iodide solution containing
0.25 mg/ml RNase. For EDU incorporation cells were fixed
in 2% formaldehyde and permeabilized by subsequent
addition of 70% ethanol. Cells were then washed in PBS
containing 0.05% Triton X-100 before detection of EdU-
substituted DNA (EdU-DNA). Detection of EdU-DNA was
performed according to the Click-iT EdU Alexa Fluor 488
Imaging Kit as per manufacturer’s instructions (Thermo
Fisher). Bulk DNA was subsequently stained with DAPI.
DNA content was measured with an LSRII flow cytometer
and subpopulations were identified using FACS Diva and
Flowing Software (Turku Centre for Biotechnology,
Finland).
Western blotting
Immunoblotting was carried out as previously described
using antibodies against HUWE1, (ab70161, Abcam), c-
MYC (ab32072, Abcam), GAPDH (ab181602, Abcam) and
ubiquitin (sc-8017, Santa Cruz, Heidelberg, Germany) and
secondary antibodies anti-mouse and anti-rabbit (DAKO,
Cambridgeshire, UK). Ubiquitinated proteins were isolated
using UbiQapture-Q (Enzo Life Sciences, Exeter, UK) to
bind both mono- and poly-ubiquitinated proteins indepen-
dent of lysine chain linkage, or tandem ubiquitin binding
entity (TUBE) antibodies specific for either K48 or K63
linkages (UM607 and UM604, Life Sensors, Malvern,
USA), according to the manufacturer’s instructions. A
proportion (25 μg) of total cell lysate was retained for use as
an input control and 250 μg of remaining lysate was bound
to the appropriate affinity matrix to capture ubiquitinated
proteins. Input controls and protein eluted from the matrix
were subsequently analyzed by immunoblotting. Blots were
visualized using WesternBright™ ECL horseradish perox-
idase substrate (Advansta, UK), scanned into the G:BOX
gel doc system (Syngene, Cambridge, UK) and analyzed
using GeneTools.
Snapshot proteomics
JJN3 cells were transduced with an NTC shRNA or shRNA
targeting HUWE1 and selected in 0.5 µg/ml puromycin 48 h
post-transduction. Following selection, cells were harvested
and lysed in a mild cell lysis buffer (50 mM Tris–HCl pH
7.5, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate,
10% glycerol, 1 mM PMSF). Fresh lysates were shipped to
AVMBiomed (Pottstown, PA) for immediate use in snap-
shot proteomics (U.M.A.P) to identify ubiquitinated sub-
strates across ~20,000 proteins. Briefly, HuProt protein
microarrays were incubated in parallel with lysates from
NTC cells and HUWE1 knockdown cells for 90 min at
room temperature and biotin-tagged TUBEs (Biotin
TUBES2, Boston Biochem) were then employed for
detection of pan-ubiquitin chains across both arrays fol-
lowed by visualization using Alexa647-conjugated strepta-
vidin. Microarrays were scanned with a GenePix 4100A
scanner (Molecular Devices) and images were gridded and
quantitated using GenePix Pro (v7) software. Median
intensities (features and local backgrounds) were utilized,
and signal to noise ratio calculated. Values were then nor-
malized to biological controls within each array. Duplicate
features (representing identical protein) were summarized
by average and standard deviation. These values were
compared between arrays (WT HUWE1 minus NTC) then
Loess transformed by print tip and location to remove
technical sources of error, resulting in the final estimate of
magnitude of change (M-value). T-test (paired, 2 tailed) was
used to assess the statistical significance of each estimate
(under the null hypothesis that M= 0).
In vivo studies
All animal experiments were approved by the University of
Sheffield Animal Ethics Committee and the UK Home
Office (PPL 70/8799) in strict compliance with the Animal
(Scientific Procedures) Act 1986. All mice were group
housed in individual ventilated cages with a 12 h light/dark
cycle and ad libitum access to food and water. Mouse
numbers (n= 8/group) were calculated prospectively using
G*Power software. End stage and in vivo analyses were
blinded.
Female, 7-9-week-old NOD scid gamma (NSG, NOD.
Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice (Charles River Labora-
tories) were randomized into groups and injected i.v. with
106 human JJN3 cells expressing NTC shRNA (n= 16) or
shHUWE1-3 (n= 16) via the tail vein. After 1 week all
L. J. Crawford et al.
mice were given doxycyline (1 mg/ml in 1% sucrose) in
drinking water and then treated with either lenalidomide
(100 mg/kg, 5×/week) or vehicle (1% methyl cellulose).
Tumor burden was monitored weekly by bioluminescent
imaging using an IVIS Lumina II (Caliper Life Sciences).
All mice were sacrificed after 2 weeks of treatment. BM
was flushed from left femora and human leukocyte antigen
(HLA) positive cells were assessed by flow cytometry to
measure tumor burden using a FACSCalibur (BD Bios-
ciences). Right femora were fixed in 10% formalin, dec-
alcified, embedded in paraffin and 3 µm longitudinal
sections were dual stained with CD138/HUWE1 or CD138/
MYC as described above.
Statistical analysis
Statistical analyses were performed in GraphPad Prisim 8.
Differences between groups were evaluated using one-way
ANOVA or Student’s t test; correlation coefficients were
evaluated using Pearson’s test; log-rank test was used for
survival analysis. Data are presented as mean ± S.D of at
least three biological replicates as indicated in figure
legends.
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